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Original Article
Positive Predictive Value of Tomosynthesis-guided 
Biopsies of Architectural Distortions Seen on Digital 
Breast Tomosynthesis and without an Ultrasound 
Correlate
Gopal R. Vijayaraghavan1, Adrienne Newburg1, Srinivasan Vedantham2
1Department of Radiology, UMass School of Medicine, Worcester, Massachusetts, 2Department of Medical Imaging, e University of Arizona College of 
Medicine, Tucson, Arizona, United States.
 INTRODUCTION
Architectural distortion (AD) is defined by the Breast Imaging Reporting and Data System 
(BI-RADS®)[1] as “distortion of normal parenchyma with no definite mass visible. is includes 
thin straight lines or spiculations radiating from a point and focal retraction, distortion, 
or straightening at the edges of the parenchyma.” AD is observed in up to 6% of screening 
mammograms.[2] AD is often subtle and is the third most common cause of missed non-
palpable breast cancer, accounting for 12–45% of missed breast cancers.[2-6] e advent of digital 
breast tomosynthesis (DBT) has allowed radiologists to identify AD more often and more 
ABSTRACT
Objective: e objective of the study was to determine the positive predictive value (PPV) of architectural 
distortions (AD) observed on digital breast tomosynthesis (DBT) and without an ultrasound (US) correlate.
Materials and Methods: In this single-institution, retrospective study, patients who underwent DBT-guided 
biopsies of AD without any associated findings on digital mammography (DM) or DBT, and without a correlate 
on targeted US exam, over a 14-month period were included in this study. All patients had DM and DBT and 
targeted US exams. e PPV was computed along with the exact 95% confidence limits (CL) using simple 
binomial proportions, with histopathology as the reference standard.
Results: A total of 45 ADs in 45 patients met the inclusion criteria. Histopathology indicated 6/45 (PPV: 13.3%, 
CL: 5.1–26.8%), ADs were malignant, including one high-risk lesion that was upgraded at surgery. ADs were 
appreciated only on DBT in 12/45 (26.7%) patients, and on both DBT and DM in 33/45 (73.3%) patients, and the 
corresponding PPV was 25% (3/12, CL: 5.5–57.2%) and 9.1% (3/33, CL: 1.9–24.3%), respectively. In all analyses, 
the observed PPV significantly exceeded the 2% probability of malignancy for Breast Imaging Reporting and Data 
System-3 diagnostic categories (P < 0.004).
Conclusions: e PPV of malignancy in DBT detected AD without an US correlate in our series of 45 cases was 
6/45 (13.3%). In the absence of an US correlate, the PPV of AD is lower than that mentioned in prior literature but 
exceeds the 2% threshold to justify DBT-guided biopsy.
Keywords: Breast, Cancer, Digital breast tomosynthesis, Architectural distortion, Positive predictive value
www.clinicalimagingscience.org
Journal of Clinical Imaging Science
*Corresponding author: 
Gopal R. Vijayaraghavan 
MD, MPH, 
Associate Professor, 
Department of Radiology, 
UMass Medical School, 
Worcester, MA-01655, 
United States.
gopal.vijayaraghavan@
umassmemorial.org
Received : 10 September 19 
Accepted : 23 October 19 
Published : 18 November 19
DOI 
10.25259/JCIS_134_2019
Quick Response Code:
Vijayaraghavan, et al.: PPV of DBT-guided biopsies of AD without US correlate
Journal of Clinical Imaging Science • 2019 • 9(53) | 2
confidently.[3,5,7-10] DBT continues to gain wider acceptance 
due to increased cancer detection and lower recall rates.[11-13]
Multiple benign and malignant etiologies can manifest 
as AD on a mammogram. e common benign causes 
are radial scar/complex sclerosing lesion (CSL), dense 
stromal fibrosis, sclerosing adenosis, post-operative scar, 
and fat necrosis. Malignant causes include invasive ductal 
carcinoma (including the tubular carcinoma subtype), 
invasive lobular carcinoma, and ductal carcinoma in situ. 
It is difficult to distinguish malignancies associated with 
AD based on imaging morphology.[2-4,7-9,14-16] e workup of 
AD includes full-field, spot compression or magnification, 
two-dimensional digital mammography (DM), full-field or 
spot-compression DBT, targeted ultrasound (US), problem-
solving magnetic resonance imaging (MRI), and/or imaging-
guided biopsy.[3,7] Although DBT-guided percutaneous 
biopsies and needle localizations are increasingly utilized, 
this capability is not yet widely available.[17] Durand et 
al. highlighted the lack of evidence-based guidelines for 
management of DBT-detected AD with no correlate with 
other imaging modalities. ey suggest either excisional 
biopsy or short term follow up (BI-RADS 3) if a DBT-based 
guidance system was unavailable.[3]
An AD with an US correlate has an increased likelihood of 
malignancy.[7,8,18] In their large series of 181 ADs, Alshafeiy 
et al.[18] found only 26 with no US correlate. Only 2 of these 
26 cases were malignant (7.7%). Partyka et al.[5] in a smaller 
study noted no malignancies in ADs without an US correlate. 
However, Freer et al.[19] noted a 47% malignancy rate (17/36) 
in their study of 36 ADs that were surgically excised. us, 
there is a wide reported range for the positive predictive 
value (PPV) of DBT-detected AD without an US correlate. 
ere are also limited data on the outcome of malignancy in 
ADs without an US correlate.
A DBT-based guidance system for performing percutaneous 
biopsies became available a few years ago. In this study, 
we focused on malignant outcomes of a subset of DBT-
detected ADs without an US correlate and without associated 
findings on DM or DBT such as a mass, asymmetry, 
or microcalcifications. e intent of this study was to 
determine if short-term follow-up, an option suggested by 
Durand et al.[3] is still appropriate considering the availability 
of DBT-guided biopsy systems.
MATERIALS AND METHODS
is single-institution, retrospective study was conducted 
in accordance with our institutional review board-approved 
and Health Insurance Portability and Accountability 
Act – compliant protocol with waiver of informed consent. 
All imaging and procedures were performed as standard of 
care.
Inclusion/exclusion criteria
e inclusion criteria were: (1) Women who underwent 
image-guided biopsies using an upright biopsy guidance 
system (Affirm®, Hologic Inc., Marlborough, MA) used 
in conjunction with a DBT system (Selenia® Dimensions®, 
Hologic Inc., Marlborough, MA) between January 2016 
and February 2017; (2) an indication of AD without an US 
correlate; (3) women who had undergone imaging evaluation 
with all three modalities – DM, DBT, and targeted US; 
(4) retrospective imaging evaluation by two fellowship-trained 
breast imagers to confirm the indication of AD without an US 
correlate; and (5) availability of biopsy pathology results in 
electronic records. Women who did not satisfy all of the above 
inclusion criteria were excluded from this study.
Retrospective data were retrieved from the electronic radiology 
database. During this period 66 upright DBT-guided biopsies 
were performed using the standard technique with six samples 
obtained using a 9G E-Viva needle (Hologic Inc., Marlborough, 
MA). On review of the electronic medical record, the indication 
for biopsy in 47/66  cases was AD without an US correlate. 
One of three breast-certified US technologists (10–20  years 
experience), who perform only breast sonograms, did all the 
scans. A  fellowship-trained breast radiologist simultaneously 
evaluates the images and if necessary, personally scans and 
obtains additional images. e 19/66 cases where the indication 
for biopsy was not AD were excluded and the remaining 
47/66  cases were eligible to be considered for the study. e 
images of these 47  cases were reviewed by two fellowship-
trained breast imagers (study authors 1 and 2) to ensure that 
all patients had undergone imaging evaluation with all three 
modalities  -  DM, DBT, and targeted US. Lack of an obvious 
mass or suspicious microcalcifications on tomosynthesis images 
and absence of a correlate on US were confirmed. During this 
review, two (2/47) cases demonstrated the question of a central 
asymmetry on DBT images and were, therefore, excluded 
from the analysis. Biopsy pathology results were available for 
all 45 patients. us, 45 patients satisfied inclusion criteria and 
none were excluded from this study.
Reference standard
All retrieved biopsy samples and surgically excised tissues 
underwent histopathological evaluation by one of two 
pathologists specializing in breast cancer with 10 and 20 years 
of experience. Since selective surgical excision of high-risk 
lesions could contribute to bias, two reference standards were 
used for the presence of malignancy: (1) Histopathology 
results from core-needle biopsy alone and (2) all available 
histopathology results that include the results from 
core-needle biopsy and from subsequent surgical excision, 
if the patient underwent surgery. A 2-year negative imaging 
follow-up was considered truth for the absence of malignancy.
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Statistical analysis
e primary aim of this study was to determine the PPV 
of AD with no associated findings on DM or DBT and 
without a correlate on targeted US. With histopathology 
results serving as the truth, the PPV was computed and the 
exact (Clopper–Pearson) 95% confidence limits (CL) were 
determined by simple binomial proportions. Fisher’s exact 
test was used to compare the outcomes from independent 
groups. e effects associated with P < 0.05 were considered 
significant. All analyses were performed using statistical 
software (SAS® version 9.4., SAS Institute Inc., Cary, NC).
RESULTS
Demographics
Forty-five patients with 45 ADs met the inclusion criteria. 
Mean (±standard deviation) age was 58.1 ± 10.7 years (range: 
28–78.7  years). Of the 45 ADs in the study, 31 were noted 
on screening exams and 14 were seen on diagnostic imaging. 
None of the 14 diagnostic cases were symptomatic. e 
indications for these diagnostic exams were short interval 
follow-up of a previously noted AD or routine annual 
evaluation in a patient with history of treated breast cancer. 
e incidence of AD did not vary with laterality in our 
cohort, with 21 and 24 lesions in the right and left breasts, 
respectively. In 12 of 45 (26.7%) patients, AD was seen only 
on DBT and not appreciated on DM. ADs were noted in both 
DM and DBT in the remaining 33 of 45  (73.3%) patients, 
with the DBT depicting the lesion better than the DM in all 
33  patients. ADs were seen in both views in 40/45  (88.9%) 
patients, on craniocaudal view only in 3/45 (6.7%) patients, 
and on mediolateral oblique view only in 2/45  (4.4%) 
patients.
Pathology of core needle biopsy and subsequent follow-up
e pathology outcomes from core-needle biopsy are 
outlined in Table  1 and subsequent follow-up is outlined 
in Table  2. Histopathology results from DBT-guided core-
needle biopsies were available for all 45 ADs, of which 5 
were malignant. Among patients with malignancies, 4/5 
were initially recalled from a screening examination and 1/5 
was from a diagnostic examination (assigned a BI-RADS 
3 on a prior exam). Figure 1 shows an example of a patient 
recalled from screening. On reviewing subsequent surgery 
and follow-up information, 13/45  patients underwent 
surgery at our institution and have been followed for 2 years; 
28/45  cases did not undergo surgery post-biopsy and have 
had imaging follow-up for 2  years; and 4/45  (8.9%) had 
breast surgery at outside facilities and were lost to follow-up. 
All radial scars with atypia are recommended surgery at our 
institution. For radial scars without atypia, patient preference 
for surgery or imaging follow-up guided management and 
6/12 patients declined surgery.
Surgical outcomes for 3/5 cancers were available and final 
surgical histopathology was concordant with imaging and 
with the histopathology from DBT-guided biopsy. e 
remaining two patients sought treatment elsewhere. Among 
18  patients with radial scar/CSL, 6  patients had associated 
Table 1: Histopathology of architectural distortions without associated findings such as a mass, focal asymmetry, or microcalcifications 
on DM and DBT, and without an ultrasound correlate (*One complex sclerosing lesion with atypical ductal hyperplasia was upgraded to 
ductal carcinoma in situ after surgical excision and is included in the malignant category).
Histology Either DM or DBT (n=45) Both DM and DBT (n=33) DBT only (n=12)
Malignant
Invasive lobular carcinoma 2 1 1
Invasive ductal carcinoma 1 1 0
Invasive ductal-lobular carcinoma 1 1 0
Ductal carcinoma in situ* 2 0 2
Total (including 1 surgical upgrade) 6 3 3
High-risk lesions
Radial scar/complex sclerosing lesion 12 10 2
Atypical ductal hyperplasia 3 2 1
Complex sclerosing lesion+atypical lobular hyperplasia 1 1 0
Complex sclerosing lesion+atypical ductal hyperplasia* 2 1 1
Total 18 14 4
Benign
Dense stromal fibrosis 18 13 5
Pseudoangiomatous stromal hyperplasia 1 1 0
Focal sclerosing lesion 1 1 0
Papillary lesion 1 1 0
Total 21 16 5
DM: Digital mammography, DBT: Digital breast tomosynthesis
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atypia (atypical ductal hyperplasia, n = 5 and atypical 
lobular hyperplasia, n = 1), of which 4 underwent surgery 
at our institution. One patient, who had CSL with atypical 
ductal hyperplasia on DBT-guided biopsy was upgraded 
to ductal carcinoma in situ following surgical excision. In 
the 2/6  patients who sought surgical treatment at another 
institution, surgical concordance with biopsy results could 
not be verified. Among the remaining 12 patients with CSL/
radial scar without atypia, 6 patients opted for surgery, and 
histopathology from surgery was concordant with core-
needle biopsy in all patients. e remaining 6 (who opted 
for imaging follow-up) have had a 2-year follow-up with no 
significant interval change on imaging. Figure  2 shows an 
example.
PPV
us, a total of 6/45 AD without associated findings on DM or 
DBT and without an US correlate were malignant, resulting 
in PPV of 13.3% (CL: 5.1–26.8%). When the histopathology 
results from core-needle biopsy alone are considered as the 
reference standard, 5/45 were malignant, resulting in PPV of 
11.1% (CL: 3.7–24.1%). If surgical pathology is considered the 
reference standard, i.e., after excluding 4 patients (2 biopsy-
proven malignancies and 2 radial scars/CSL with atypia) 
who were lost to follow-up, 4/41 (9.8%; CL: 2.7–23.1%) were 
malignant. Irrespective of the reference standard, the cancer 
rate of DBT-detected AD without an US correlate exceeded 
the 2% threshold of BI-RADS 3 (P < 0.0002). Among the 
33 AD seen on both DM and DBT, 3/33 were malignant, 
resulting in a PPV of 9.1% (CL: 1.9–24.3%). DM missed 
12/45 (26.7%; CL: 14.6–41.9%) ADs and these were detected 
only on DBT. ree of these 12 ADs were malignant, resulting 
in PPV of 25% (CL: 5.5–57.2%) for AD seen only on DBT. 
None of the ADs were seen only on DM, but not on DBT.
DISCUSSION
In our series of 45 DBT-guided biopsy of AD, 5/45 were 
malignant on biopsy pathology (an additional cancer was 
noted at a subsequent surgical biopsy of a high-risk lesion), 
18/45 documented a high-risk lesion, and 22/45 had benign 
pathology. e PPV of malignancy in our cohort of 45 cases 
was 9.8–13.3%, depending on the reference standard. 
Importantly, irrespective of the reference standard, the PPV 
exceeded the 2% threshold of BI-RADS 3 (P < 0.0002). 
Considering the availability of DBT-guided biopsy systems, 
we do not support a BI-RADS 3 recommendation as 
mentioned in earlier literature.[3] We recommend biopsy as 
the next step.
Figure  1: A  59-year-old woman recalled from screening 
mammography for the right upper outer quadrant architectural 
distortion (AD). e AD (arrows in A and C; ellipse in A) was well 
appreciated in digital breast tomosynthesis (DBT) (A: Mediolateral 
oblique view and C: Craniocaudal view) compared to digital 
mammography (B: Mediolateral oblique view and D: Craniocaudal 
view). No correlate was identified on the targeted ultrasound 
exam. Subsequent DBT-guided biopsy indicated invasive lobular 
carcinoma.
A B
C D
Table 2: Summary of post-biopsy follow-up  (n=45). Post-biopsy, 17/45 underwent surgery, of which 13/17 were at our institution and 
the remainder (4/17) outside our institution and hence were lost to follow-up. e remaining 28/45 cases (22 benign and 6 radial scars/
complex sclerosing lesions without atypia) have had 2-year imaging follow-up to date that was negative.
Malignant Radial scar/complex 
sclerosing lesion with atypia
Radial scar/complex sclerosing 
lesion without atypia
Benign Total
Biopsy outcomes 5 6 12 22 45
Post-biopsy surgery at our 
institution
3 4 (1 upgrade) 6 0 13
Post-biopsy surgery outside our 
institution and lost to follow-up
2 2 0 0 4
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e likelihood of a malignant outcome in biopsies of ADs varies 
from 25% to 75%.[4,5,8,9,14,15,18,19] Most studies were before the 
introduction of DBT and were biopsied under DM, US, or MRI 
guidance.[4,5,8] AD is being diagnosed more often and confidently 
in DBT.[3,5,7-10] In the initial years after the introduction of DBT, 
a DBT-based biopsy guidance system was unavailable. Hence, in 
several studies after the introduction of DBT, most of the ADs 
had correlates on other modalities, which were used for biopsy 
guidance.[5,9,19] Our study differs in that every subject had all 
three imaging exams (acquired DM, DBT, and US) and all ADs 
were detected by DBT. Synthesized mammography is not used 
in our institution. ere were no associated findings on DM or 
DBT, there was no US correlate, and biopsies were performed 
under DBT guidance. Hence, direct comparison with prior 
studies is challenging, where appropriate, selective cohorts from 
prior studies were used for comparison.
An early study using pre-operative DBT-guided needle 
localization followed by surgical excision of DBT-detected 
lesions that were occult on other modalities (DM, US, and 
MRI, if performed), reported 17/36 (47%) were malignant.[19] 
In this study, 12 ADs were detected by DBT alone, of which 
3 were malignant, and the cancer rate 25% (3/12) was not 
significantly different (P = 0.311, Fisher’s exact test). e 
DBT-guided pre-surgical needle localization required the 
expertise of radiologists, surgeons, and anesthesiologists 
and involved operating room time.[15] is makes needle 
localization less cost-effective.
Bahl et al. reported that AD is seen more often on DBT than 
on DM and that 31/106 (29.2%) DBT-detected AD without 
an US correlate were malignant.[8] Our study also observed 
that more AD was detected on DBT than on DM (n = 45 vs. 
n = 33), and the PPV in our study was marginally different 
(P = 0.0404, Fisher’s exact test). However, in Bahl et al.,[8] 
some of the patients had associated findings on DM, whereas 
there were none in our study. Subsequent to the availability 
of DBT-based biopsy guidance system, there have been a 
few studies.[18,20,21] Schrading et al. reported on the technical 
comparison between DBT-guided and stereotactic biopsies 
and noted a reduction in procedure time with DBT-guided 
biopsies.[21] Waldherr et al. reported on outcomes from 
DBT-guided biopsies of findings without a US correlate that 
included 24 patients with ADs, of which 13 were malignant 
(54%).[20] e PPV significantly differed from our study 
(P = 0.0005, Fisher’s exact test). It is unclear if the ADs 
included in their study had associated findings on DM or 
DBT. None of the ADs in our study had associated findings 
on DM or DBT.
In a study comparing outcomes for DM-detected and DBT-
detected AD, when lesions without a US correlate alone 
are considered, 5/45  (11.1%) were malignant, of which 
2/26  (7.7%) were detected by DBT alone.[18] In our study, 
3/33 (9.1%) DM-detected AD and 3/12 (25%) DBT-detected 
AD were malignant and the PPVs were not significantly 
different (P > 0.301, Fisher’s exact test). One would expect 
a higher PPV in DM-detected ADs; however, DM-detected 
ADs have higher likelihood of an US correlate,[18] and 
patients with US correlate were excluded in our study. 
Patel et al. reported that 9/34 DBT-detected ADs without 
US correlate were malignant on DBT-guided core-needle 
biopsy and the PPV (26%) reported in that study[22] was not 
significantly different from our study (P = 0.135, Fisher’s 
exact test).
To the best of our knowledge, our cohort, though 
relatively small, of 45 DBT-detected ADs without any 
associated findings such as a mass, a focal asymmetry, or 
microcalcifications on DM or DBT and without an US 
correlate and biopsied under DBT-guidance may be the 
largest to date. Literature on pathology outcomes of ADs 
seen on DBT without associated findings on DM or DBT 
and without an US correlate is relatively sparse. In our cohort 
of 45 ADs seen on DBT, the cancer rate was 6/45  (13.3%). 
e 95% CLs (5.1–26.8%) indicate that the likelihood of 
malignancy may be as high as 27%.
A high-risk lesion was demonstrated in 18/45 (40%) biopsies, 
as outlined in Tables 1 and 2. Patients with high-risk lesions 
are selectively recommended for surgery based on imaging 
and core-needle histopathology at most institutions. e 
upgrade rates vary from <2% to 18%.[15,16,23,24] In our opinion, 
excluding patients who did not undergo surgery could 
contribute to statistical bias by preferentially decreasing the 
denominator and hence, resulting in higher PPV. Hence, for 
Figure  2: A  50-year-old woman recalled from screening 
mammography for right lower inner quadrant architectural 
distortion (AD). e AD (ellipse and arrow in A; craniocaudal view) 
was well appreciated in digital breast tomosynthesis (DBT) (A). No 
correlate was identified on targeted ultrasound. Histopathology 
from biopsy indicated radial scar/complex sclerosing lesion without 
atypia. 2-year follow-up DBT (B) shows biopsy changes and 
adjacent biopsy-marker.
A B
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completeness, the PPVs are reported with histopathology 
results from core-needle biopsy alone and from all available 
histopathology that include the results from both core-
needle biopsy and from surgery (if performed). We conclude 
that the probability of cancer would be no <5.1% (lower 
bound of 95% CL). e management of radial scar is 
evolving and debatable. Current literature suggests that not 
all radial scars merit surgical excision. e cancer upgrade 
rates are low.[15,16] e PPV of DBT guided biopsies of AD 
at our center exceeds the 2% threshold of BI-RADS 3. Since 
differentiating benign from malignant causes of AD on 
imaging is difficult, we recommend DBT-guided biopsy 
of AD as the next step in the management of AD at our 
institute.
Our study had limitations. Evaluation of AD is compounded 
by interobserver variability.[25] We only included patients 
biopsied with a DBT guidance system with an initial 
diagnosis of AD. ere is a possibility that additional patients 
with AD may have been excluded if the initial diagnosis was 
different. e study reflects the initial outcomes at a single 
institution. Some patients (8/18) with radial scars in our 
series did not have the benefit of surgical pathology. e 
patients with benign histology (22/45) have had a 2-year 
imaging follow-up to date that was negative, but long-term 
follow-up would be useful.
CONCLUSIONS
e PPV of DBT-detected ADs without a correlate on targeted 
US was 13% (CL: 5.1–26.8%). Our findings corroborate prior 
literature with a smaller sample size. ere is need for follow-
up studies with larger sample size to confirm the PPV of AD 
detected on DBT and without an US correlate.
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